Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

Infection and viral entry of SARS-CoV-2 crucially depends on the binding of its Spike protein to angiotensin converting enzyme 2 (ACE2) presented on host cells. Glycosylation of both proteins is critical for this interaction. Recombinant soluble human ACE2 can neutralize SARS-CoV-2 and is currently...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Tümay Capraz, Nikolaus F Kienzl, Elisabeth Laurent, Jan W Perthold, Esther Föderl-Höbenreich, Clemens Grünwald-Gruber, Daniel Maresch, Vanessa Monteil, Janine Niederhöfer, Gerald Wirnsberger, Ali Mirazimi, Kurt Zatloukal, Lukas Mach, Josef M Penninger, Chris Oostenbrink, Johannes Stadlmann
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: eLife Sciences Publications Ltd 2021-12-01
Loạt:eLife
Những chủ đề:
Truy cập trực tuyến:https://elifesciences.org/articles/73641
Miêu tả
Tóm tắt:Infection and viral entry of SARS-CoV-2 crucially depends on the binding of its Spike protein to angiotensin converting enzyme 2 (ACE2) presented on host cells. Glycosylation of both proteins is critical for this interaction. Recombinant soluble human ACE2 can neutralize SARS-CoV-2 and is currently undergoing clinical tests for the treatment of COVID-19. We used 3D structural models and molecular dynamics simulations to define the ACE2 N-glycans that critically influence Spike-ACE2 complex formation. Engineering of ACE2 N-glycosylation by site-directed mutagenesis or glycosidase treatment resulted in enhanced binding affinities and improved virus neutralization without notable deleterious effects on the structural stability and catalytic activity of the protein. Importantly, simultaneous removal of all accessible N-glycans from recombinant soluble human ACE2 yields a superior SARS-CoV-2 decoy receptor with promise as effective treatment for COVID-19 patients.
số ISSN:2050-084X